scholarly journals Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission

2009 ◽  
Vol 42 (5) ◽  
pp. 484-487 ◽  
Author(s):  
Sergio Sosa-Estani ◽  
Estela Cura ◽  
Elsa Velazquez ◽  
Cristina Yampotis ◽  
Elsa Leonor Segura
Keyword(s):  
Trypanosoma Cruzi ◽  
Young Women ◽  
Serological Tests ◽  
Congenital Transmission ◽  
Cruzi Infection ◽  
Efficacy Of Treatment

The objective was to detect Trypanosoma cruzi infection in 32 children in Salta, Argentina, born to 16 chronically infected young women who were treated with benznidazole. Tests were performed to assess the efficacy of treatment after 14 years. At the end of the follow up, 87.5% of the women were non-reactive to EIA tests, 62.5% to IHA and 43.8% to IFA. 62.5% of the women were non-reactive according to two or three serological tests. No infected children were detected among the newborns of mothers treated before their pregnancy.

scholarly journals Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies

PLoS ONE ◽  
2015 ◽  
Vol 10 (10) ◽  
pp. e0139363 ◽  
Author(s):  
Yanina Sguassero ◽  
Cristina B. Cuesta ◽  
Karen N. Roberts ◽  
Elizabeth Hicks ◽  
Daniel Comandé ◽  
...  
Keyword(s):  
Systematic Review ◽  
Trypanosoma Cruzi ◽  
Serological Tests ◽  
Follow Up Studies ◽  
Cruzi Infection

scholarly journals Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole

2020 ◽  
Vol 14 (9) ◽  
pp. e0008726
Author(s):  
Claudia Magalhães Calvet ◽  
Tatiana Araújo Silva ◽  
Diane Thomas ◽  
Brian Suzuki ◽  
Ken Hirata ◽  
...  
Keyword(s):  
Trypanosoma Cruzi ◽  
Chagas Disease ◽  
Long Term Follow Up ◽  
Cruzi Infection

scholarly journals New evidence of spontaneous cure in human Chagas' disease

2003 ◽  
Vol 36 (1) ◽  
pp. 103-107 ◽  
Author(s):  
Sonia S. Francolino ◽  
Antonio Fernandez Antunes ◽  
Rodolfo Talice ◽  
Rachel Rosa ◽  
Joel Selanikio ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Trypanosoma Cruzi ◽  
Chagas Disease ◽  
Acute Phase ◽  
Clinical Data ◽  
Specific Treatment ◽  
Serological Tests ◽  
Spontaneous Cure ◽  
New Evidence ◽  
Cruzi Infection

A new case of spontaneous cure of human Chagas' disease is described in Uruguay. An 87-year-old man who had a typical acute phase of Trypanosoma cruzi infection in 1947 and never received specific treatment against the disease, when examined in 1998 revealed several completely negative parasitological and serological tests, including traditional serology, PCR and flow cytometry. As a whole, such findings fulfill the current criteria to define the cure of Chagas' disease. Clinical data suggest the possibility of a benign evolution of Chagas' disease in this case, but the basic findings (slight cardiac and esophageal impairment) could also be due to the advanced age of the patient.

scholarly journals The Trypomastigote Small Surface Antigen from Trypanosoma cruzi Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease

2017 ◽  
Vol 55 (12) ◽  
pp. 3444-3453 ◽  
Author(s):  
Virginia Balouz ◽  
Luciano J. Melli ◽  
Romina Volcovich ◽  
Guillermo Moscatelli ◽  
Samanta Moroni ◽  
...  
Keyword(s):  
Trypanosoma Cruzi ◽  
Chagas Disease ◽  
Surface Antigen ◽  
Rapid Assessment ◽  
Drug Efficacy ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serological Tests ◽  
Small Surface ◽  
Content Type

ABSTRACTChagas disease is caused by the protozoan parasiteTrypanosoma cruzi. Assessment of parasitological cure upon treatment with available drugs relies on achieving consistent negative results in conventional parasitological and serological tests, which may take years to assess. Here, we evaluated the use of a recombinantT. cruziantigen termed trypomastigote small surface antigen (TSSA) as an early serological marker of drug efficacy inT. cruzi-infected children. A cohort of 78 pediatric patients born toT. cruzi-infected mothers was included in this study. Only 39 of the children were infected withT. cruzi, and they were immediately treated with trypanocidal drugs. Serological responses against TSSA were evaluated in infected and noninfected populations during the follow-up period using an in-house enzyme-linked immunosorbent assay (ELISA) and compared to conventional serological methods. Anti-TSSA antibody titers decreased significantly faster than anti-whole parasite antibodies detected by conventional serology both inT. cruzi-infected patients undergoing effective treatment and in those not infected. The differential kinetics allowed a significant reduction in the required follow-up periods to evaluate therapeutic responses or to rule out maternal-fetal transmission. Finally, we present the case of a congenitally infected patient with an atypical course in whom TSSA provided an early marker forT. cruziinfection. In conclusion, we showed that TSSA was efficacious both for rapid assessment of treatment efficiency and for early negative diagnosis in infants at risk of congenitalT. cruziinfection. Based upon these findings we propose the inclusion of TSSA for refining the posttherapeutic cure criterion and other diagnostic needs in pediatric Chagas disease.

scholarly journals Evaluation of Serological Tests To Identify Trypanosoma cruzi Infection in Humans and Determine Cross-Reactivity with Trypanosoma rangeli and Leishmania spp.

2007 ◽  
Vol 14 (8) ◽  
pp. 1045-1049 ◽  
Author(s):  
Zuleima C. Caballero ◽  
Octavio E. Sousa ◽  
Waldelania P. Marques ◽  
Amadeo Saez-Alquezar ◽  
Eufrosina S. Umezawa
Keyword(s):  
Trypanosoma Cruzi ◽  
Synthetic Peptides ◽  
Cross Reactivity ◽  
Reference Test ◽  
Trypanosoma Rangeli ◽  
Serological Tests ◽  
Western Blot Assay ◽  
Leishmania Spp ◽  
Cruzi Infection ◽  
Secreted Antigens

ABSTRACT Five commercially available enzyme-linked immunosorbent assays (ELISAs), one in-house ELISA, and two hemagglutination assays were evaluated to determine their diagnostic accuracy for Chagas' disease in two studies. In study 1, ELISA kits showed 100% sensitivity, but specificities ranged from 82.84% to 100% when leishmaniasis cases were included and from 95.57% to 100% when leishmaniasis cases were excluded. Kits using recombinant antigens or synthetic peptides are more specific than those using crude extracts from Trypanosoma cruzi epimastigote forms. Kits evaluated in Panama, in study 2, showed 75% to 100% sensitivity and 97.12% to 100% specificity. These data were obtained by using a Western blot assay with T. cruzi trypomastigote excreted-secreted antigens as a reference test to confirm T. cruzi infection.

scholarly journals Trypanosoma cruzi: avirulence of the PF strain to Callithrix marmosets

1981 ◽  
Vol 14 (1) ◽  
pp. 73-80
Author(s):  
Humberto Menezes
Keyword(s):  
Body Weight ◽  
Trypanosoma Cruzi ◽  
Callithrix Jacchus ◽  
Blood Cultures ◽  
Serological Tests

Callithrix jacchus geoffroy marmosets (HumBol. 1812) were injected once subcutaneously with 10.000 parasites/g body weight and followed for a period of six months. The PF strain of Trypanosoma cruzi was used. Follow-up was done through blood cultures, xenodiagnosis, serological tests, and ECG. A small number of normaI animais served as control.

scholarly journals Towards a New Strategy for Diagnosis of Congenital Trypanosoma cruzi Infection

2017 ◽  
Vol 55 (5) ◽  
pp. 1396-1407 ◽  
Author(s):  
Alba Abras ◽  
Carmen Muñoz ◽  
Cristina Ballart ◽  
Pere Berenguer ◽  
Teresa Llovet ◽  
...  
Keyword(s):  
Trypanosoma Cruzi ◽  
Latin American ◽  
Serological Test ◽  
Igg Antibodies ◽  
Childbearing Age ◽  
Serological Tests ◽  
Content Type ◽  
Congenital Transmission ◽  
Screening Programs ◽  
New Strategy

ABSTRACTThe immigration of Latin American women of childbearing age has spread the congenital transmission of Chagas disease to areas of nonendemicity, and the disease is now a worldwide problem. Some European health authorities have implemented screening programs to prevent vertical transmission, but the lack of a uniform protocol calls for the urgent establishment of a new strategy common to all laboratories. Our aims were to (i) analyze the trend of passive IgG antibodies in the newborn by means of five serological tests for the diagnosis and follow-up of congenitalTrypanosoma cruziinfection, (ii) assess the utility of these techniques for diagnosing a congenital transmission, and (iii) propose a strategy for a prompt, efficient, and cost-effective diagnosis ofT. cruziinfection. In noninfected newborns, a continuous decreasing trend of passive IgG antibodies was observed, but none of the serological assays seroreverted in any the infants before 12 months. From 12 months onwards, serological tests achieved negative results in all the samples analyzed, with the exception of the highly sensitive chemiluminescent microparticle immunoassay (CMIA). In contrast, in congenitally infected infants, the antibody decline was detected only after treatment initiation. In order to improve the diagnosis of congenitalT. cruziinfection, we propose a new strategy involving fewer tests that allows significant cost savings. The protocol could start 1 month after birth with a parasitological test and/or a PCR. If negative, a serological test would be carried out at 9 months, which if positive, would be followed by another at around 12 months for confirmation.

scholarly journals New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up

2020 ◽  
Vol 64 (9) ◽  
Author(s):  
María Gabriela Álvarez ◽  
Juan Carlos Ramírez ◽  
Graciela Bertocchi ◽  
Marisa Fernández ◽  
Yolanda Hernández ◽  
...  
Keyword(s):  
Trypanosoma Cruzi ◽  
Nuclear Dna ◽  
Parasite Load ◽  
Serological Tests ◽  
Content Type ◽  
Monocyte Chemoattractant Protein 1 ◽  
Specific Antibodies ◽  
Intermittent Administration ◽  
Low Rate

ABSTRACT In a pilot study, we showed that the intermittent administration of benznidazole in chronic Chagas disease patients resulted in a low rate of treatment suspension and therapeutic failure, as assessed by quantitative PCR (qPCR) at the end of treatment. Here, a 3-year posttreatment follow-up study of the same cohort of patients is presented. The treatment scheme consisted of 12 doses of benznidazole at 5 mg/kg of body weight/day in two daily doses every 5 days. Parasite load, Trypanosoma cruzi-specific antibodies, and serum chemokine levels were measured prior to treatment and after a median follow-up of 36 months posttreatment by DNA minicircle kinetoplastid and nuclear DNA satellite sequence qPCR methods, conventional serological techniques, a Luminex-based assay with recombinant T. cruzi proteins, and a cytometric bead array. At the end of follow-up, 14 of 17 (82%) patients had negative qPCR findings, whereas three of 17 (18%) had detectable nonquantifiable findings by at least one of the qPCR techniques. A decline in parasite-specific antibodies at 12 months posttreatment was confirmed by conventional serological tests and the Luminex assays. Monocyte chemoattractant protein 1 levels increased after treatment, whereas monokine induced by gamma interferon levels decreased. New posttreatment electrocardiographic abnormalities were observed in only one patient who had cardiomyopathy prior to treatment. Together, these data strengthen our previous findings by showing that the intermittent administration of benznidazole results in a low rate of treatment suspension, with treatment efficacy comparable to that of a daily dose of 5 mg/kg for 60 days.

scholarly journals The vaccination of h uman beings with live avirulent vaccine of Trypanosoma cruzi: A two year follow-up of the first two cases

1972 ◽  
Vol 6 (4) ◽  
pp. 177-180
Author(s):  
Humberto Menezes
Keyword(s):  
Trypanosoma Cruzi ◽  
Large Dose ◽  
Clinical Test ◽  
Human Beings ◽  
Serological Tests ◽  
Negative Results

A two year follow-up of the first two volunteers vaccinated icith the live PF Trypanosoma cruzi strain demonstrated that the parasitological and clinical test were negative during and after that period. Of the serological tests employed, the CFT presented, in only one case, conflicting results, particulary in one laboratory and among different laboratories. However negative results were greater than all doubtful and positive one combined. The IFT icere negative in both patients. Some comments are made about the sensibility and specificity of these tests. The author concluded that the vaccine, in spite of the very large dose used in these cases, seems to be safe for human beings.

Sign in / Sign up

Export Citation Format

Share Document